Compare YSG & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSG | FATE |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.3M | 260.0M |
| IPO Year | 2020 | 2013 |
| Metric | YSG | FATE |
|---|---|---|
| Price | $2.03 | $1.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $5.72 |
| AVG Volume (30 Days) | 43.4K | ★ 1.5M |
| Earning Date | 11-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | $4.74 | N/A |
| Revenue Next Year | $11.48 | $18.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.67 | $0.95 |
| 52 Week High | $6.59 | $3.23 |
| Indicator | YSG | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 38.36 | 20.53 |
| Support Level | $1.67 | $1.07 |
| Resistance Level | $3.05 | $1.38 |
| Average True Range (ATR) | 0.21 | 0.17 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 36.42 | 0.00 |
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.